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Background: Obstructive sleep apnoea syndrome (OSAS) affects an estimated 2–4% of the middle aged
population. Meta-analyses of randomised controlled trials have shown that the severe presentation of the
syndrome (apnoea hypopnoea index (AHI) .30/hour) is effectively treated with continuous positive
airway pressure (CPAP). Until recently there have been insufficient data to determine whether CPAP
improves sleepiness in the larger subgroup with mild to moderate OSAS (AHI 5–30/hour).
Methods: A systematic search of Medline and a hand search identified seven randomised controlled trials
where CPAP was compared with either a placebo or with conservative management in the treatment of
mild to moderate OSAS (AHI 5–30/hour). All trials used the Epworth Sleepiness Scale (ESS), four used the
Multiple Sleep Latency Test (MSLT), and three used the Maintenance of Wakefulness Test (MWT) to
measure sleepiness.
Results: Meta-analyses indicated that CPAP significantly reduced subjective daytime sleepiness (ESS) by
1.2 points (95% CI 0.5 to 1.9, p = 0.001), improved objective daytime wakefulness (MWT) by 2.1 minutes
(95% CI 0.5 to 3.7, p = 0.011), but did not affect objective daytime sleepiness (MSLT, mean benefit
20.2 minutes, 95% CI 21.0 to 0.6, p = 0.6). The two significant effects were small (effect size ,0.30).
Conclusions: CPAP elicits small improvements in subjective sleepiness and objective wakefulness in people
with mild to moderate OSAS. However, the effects on sleepiness are of limited clinical significance.
O
bstructive sleep apnoea syndrome (OSAS) is a
common sleep breathing disorder characterised by
repetitive collapse or narrowing of the airway result-
ing in intermittent blood oxygen desaturations and frag-
mented sleep. OSAS, coupled with daytime sleepiness, affects
at least 2–4% of the middle aged population.1 Sleepiness is a
common presenting symptom of OSAS and may be measured
by both subjective2 and objective methods.3 4 Other present-
ing symptoms include loud sonorous snoring, cognitive
confusion, poor executive functioning, impaired quality of
life, morning headaches, and hypertension. It is well
established that continuous positive airway pressure
(CPAP)5 effectively reduces obstructive sleep disordered
breathing to levels regarded as normal. The most recent
meta-analysis of published randomised controlled trials has
also shown that CPAP effectively reduces both subjective and
objective daytime sleepiness in people with severe OSAS.6
However, most people with the condition have mild to
moderate severity OSA, which is defined by an apnoea
hypopnoea index (AHI) of 5–30/hour plus daytime sleepi-
ness.7 8 From the four randomised controlled trials9–12 avail-
able in 2001, Patel and colleagues6 were unable to conclude
that CPAP was effective in reducing daytime sleepiness in
this patient population. However, this sub-analysis included
one additional study that specifically investigated the use of
CPAP in patients with AHI .30/hour but no daytime
sleepiness.13 That study addressed a separate question
regarding treatment of severe sleep disordered breathing
without marked daytime sleepiness (AHI .30) and does not
bear directly on the effectiveness of CPAP in mild to
moderate OSAS. Since the meta-analysis by Patel and
colleagues,6 we have published three additional randomised
controlled trials examining the effectiveness of CPAP
treatment for patients with mild to moderate OSAS.14–16
Here we report on a new systematic search and meta-analysis
to quantify the effect of CPAP on daytime sleepiness in
people with mild to moderate OSAS.
METHODS
Evidence search
A systematic review of the current literature was undertaken
using Medline publications from 1 January 1994 to 31
December 2004. Keywords used to identify randomised
controlled trials of CPAP in the treatment of mild to moderate
OSAS published in English were (apnoea.af or apnea.af or
hypopnoea.af or hypopnea.af) and (CPAP.af or continuous
positive airway pressure.af or positive airways pressure.af or
positive pressure.af) and (randomized controlled trial.pt or .ti
or clinical trial.pt or .ti). Suffixes indicated search fields
used in MEDLINE (.af = all fields, .pt = publication type,
.ti = title). The authors’ personal knowledge, previous rando-
mised trials, meta-analyses and reviews (including previous
Cochrane reviews) were used as additional bibliographic
sources.
Selection of published studies
Two investigators (NSM and MB) independently applied the
following selection rules to the studies identified in the
systematic search. Only studies that were randomised
controlled trials with treatment arms of at least 1 week of
manually titrated CPAP therapy undertaken on adult patients
Abbreviations: AHI, apnoea hypnoea index; BMI, body mass index;
CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness
Scale; MSLT, Multiple Sleep Latency Test; MWT, Maintenance of
Wakefulness Test; OSAS, obstructive sleep apnoea syndrome
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with OSAS were considered. One of the arms had to be either
conservative management or placebo. Conservative manage-
ment of OSAS usually includes advice about weight loss,
sleep hygiene, adoption of non-supine sleep posture, and
avoidance of alcohol and sedatives. Acceptable placebos
included orally ingested placebo tablets or sham CPAP
devices that did not improve overnight indices of sleep
disordered breathing compared with baseline polysomno-
graphic reports. Unacceptable comparisons included any
device that improved sleep disordered breathing such as
suboptimally pressured but partially therapeutic CPAP, or
any surgical techniques including sham surgery or sham or
ineffective mandibular advancement splints. Studies not
exclusively analysing mild to moderate OSAS classification
(AHI specified as 5–30/hour) were excluded. To be included,
trials had to measure the Epworth Sleepiness Scale (ESS; a
measure of trait subjective sleepiness, self-reported likelihood
of dozing in common situations2), and/or the Multiple Sleep
Latency Test (MSLT; a measure of state objective sleepiness,
propensity to fall asleep3), and/or the Maintenance of
Wakefulness Test (MWT, a measure of state objective
wakefulness, the ability to resist sleep4). The ESS is a pencil
and paper measure of the likelihood of falling asleep in eight
everyday situations (each scored between 0 and 3) and is
expressed as a score between 0 (not sleepy) and 24
(extremely sleepy). The two objective methods quantify
daytime sleepiness by electrophysiologically measuring the
average sleep latency across a number of nap opportunities in
a single day. They mainly differ by the instruction to patients
to ‘‘go to sleep’’ (MSLT) or to ‘‘stay awake’’ (MWT).
Data abstraction and trial quality assessment
Study and patient characteristics retrieved for each trial
included: number of patients, placebo type, trial structure,
length of follow up, sex balance, mean age, mean body mass
index (BMI; kg/m2), mean AHI, method of measuring airflow
(thermistor or pressure transducer), dropout rate, mean
CPAP use per night, country of origin, and baseline severity of
sleepiness measured by the ESS, MWT, and/or MSLT. The
primary data analyses required the mean (SE) of the placebo
adjusted effects of CPAP on the ESS, MSLT or MWT. The
Jadad score17 is a validated metric used to assess the quality
of randomised controlled trials. Points are awarded from 0 to
5 for appropriate double blinding, appropriate randomisation,
and the clear reporting of trial dropouts and exclusions.
Jadad scores can be used in a meta-analysis to assess whether
trial quality has affected the size of the treatment effect and
to exclude trials of lower quality. Jadad scores were
independently calculated by two investigators for all included
trials.
Data synthesis and statistical analysis
The differences in treatment effect between CPAP and control
and their standard errors were not always calculable from
information in the published papers. However, Patel and
colleagues6 have recently collected and published this
information from the original authors of the four papers
published before 2001.
The mean differences in treatment responses between
CPAP and placebo groups and the standard error of that
difference from individual studies were meta-analysed
(META) using Stata Version 7.0 (Stata Corp, College
Station, TX, USA). Pooled estimates of treatment responses
were calculated with both fixed and random effects model
assumptions. Heterogeneity in treatment effect between trials
was tested for using the Q statistic. Meta-regressions
(METAREG) were performed to explore the possible sources
of any observed heterogeneity in treatment effects. Variables
potentially associated with CPAP efficacy (trial and patient
characteristics) were successively incorporated into a single
covariate model to assess their contribution to heterogeneity.
Summary estimates were also calculated excluding each
study sequentially to measure the influence of individual
study effects on the pooled estimate (METAINF). Publication
bias was evaluated visually using the funnel plot and
statistically (METABIAS) using Egger’s and Begg’s tests.
Effect sizes18 were calculated by dividing the mean size of the
effect by the baseline standard deviation of a suitable
published comparison group of 110 untreated Australian
patients with mild to moderate OSA.19
RESULTS
Systematic review
The systematic search of Medline identified 295 studies of
further interest. An additional suitable study published
outside the search dates was also included.16 The search
terms used were not specific to our question. Thus, many of
the studies identified were not randomised controlled trials,
did not investigate OSAS, or involved paediatric patients or
patients with OSAS and other serious co-morbidities. Many
unsuitable trials investigated CPAP (or a similar such device)
compared with mandibular advancement splints, autotitrat-
ing CPAP, bi-level PAP, or surgical procedures. A number of
trials used what were described as ‘‘placebo CPAP
machines’’.20–25 On closer inspection these machines substan-
tially reduced AHI and thus were not placebo devices.
Another trial compared positional therapy with CPAP in a
group of patients who had largely mild to moderate
positional OSAS.26 Thus, the positional therapy might be
expected to be beneficial to this subgroup and was not a valid
placebo. After reviewing the abstracts of the remaining
studies, 28 were randomised placebo/conservative manage-
ment controlled trials of CPAP. Both reviewers independently
Number of studies identified by





RCTs with usable information
included in meta-analyses:
n=7
Studies available for analysis
of each outcome:
Epworth scale n=7
Multiple sleep latency test n=4
Maintenance of wakefulness
test n=3
Non-OSA, non adult, multiple
comorbidity studies excluded
n=76







Figure 1 Trial inclusion flow chart.
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agreed that seven of these investigated mild to moderate
OSAS and were suitable for inclusion. Figure 1 shows the trial
inclusion flow chart. All seven studies used the ESS,9–12 14–16
four used the MSLT10–12 14 and the remaining three used the
MWT.9 15 16 The characteristics of the included trials are
summarised in table 1, and table 2 summarises the patient
characteristics from each of the trials. Five of the seven
studies used nasal thermistors9 10 12 14 15 to measure airflow
while the remaining two used nasal pressure11 16 in accor-
dance with recent guidelines.8 Trials using nasal thermistors
might include more severely afflicted OSAS patients as this
method is less sensitive to breathing disturbances than nasal
pressure measurements.
Six studies scored 3 on the Jadad scale of trial quality. All
these had adequate descriptions of trial dropouts and
withdrawals in addition to being appropriately randomised.
In one study it was unclear why dropouts had occurred.11 No
studies were truly double blind as CPAP titrations require
that at least some of the patients’ interactions with sleep staff
require those staff being unblinded. This holds even where
placebo CPAP devices are used.16
Meta-analyses
After controlling for placebo effects, Epworth scores were
significantly improved by CPAP by 1.2 points (95% CI 0.5 to
1.9, p = 0.001, fig 2). The random effects model was used
because effects on the ESS were heterogeneous (Q = 13.1,
df = 6, p = 0.04). Meta-regression indicated that heterogene-
ity was only related to one of the trial or patient
characteristics extracted from the studies (tables 1 and 2
and also thermistor or pressure transducer measurement of
SDB). Studies that had lower dropout rates had larger
reductions in Epworth scores (Z = 2.38, p = 0.02). Mean
compliance with CPAP therapy did not explain the hetero-
geneity in improvements on the ESS. CPAP still had a small
but significantly greater than zero effect when crossover and
parallel trials were analysed separately.
CPAP treatment led to an improvement in the MWT of
2.1 minutes (95% CI 0.5 to 3.7, p = 0.011) when using both
fixed and random effects methods (fig 3). MWT effects were
not heterogeneous (Q = 1.3, df = 2, p = 0.53). Only two of the
studies measured MWT at baseline and were able to quantify
the placebo effect. Barnes et al15 found a significant
2.7 minute worsening on placebo and Marshall et al16 found
a non-significant 3.1 minute worsening while on placebo.
These worsening sleep latencies contributed to the net effect
of CPAP shown in fig 3.
The MSLT was used in four studies and worsened by a
non-significant 0.2 minutes (95% CI 21.0 to 0.6, p = 0.74)
with CPAP treatment after controlling for placebo effects
using both fixed and random effects methods (fig 4). The
effects on MSLT were not heterogeneous (Q = 1.2, df = 3,
p = 0.74). A comparison analysis of MSLT and MWT latencies
showed that the difference in sensitivities of 20.2 minutes
and 2.1 minutes, respectively, was significant (Mann-
Whitney U test, Z = 2.1, p = 0.03).
No single trial, when removed, significantly affected the
overall estimate of effects. No evidence of bias was observed
Table 1 Characteristics of included studies









Engleman10 16 and 9 Pill Y 4 11% MSLT 3
Redline12 97 CT N 10.5 13% MSLT 3
Engleman9 34 Pill Y 4 8% MWT 3
Monasterio11 125 CT N 24 12% MSLT 2
Barnes14 28 Pill Y 8 33% MSLT 3
Barnes15 80 Pill N 12 30% MWT 3
Marshall16 29 Sham CPAP Y 3 6% MWT 3
CT, conservative treatment; CPAP, continuous positive airway pressure; MSLT, Multiple Sleep Latency Test; MWT, Maintenance of Wakefulness Test.
















Engleman10 52 75% (12) 30 2.8 14 10
Redline12 48 52% (50) 33 3.1 10 10
Engleman9 44 61% (21) 30 2.8 13 NB
Monasterio11 54 86% (108) 29 4.8 12 10.5
Barnes14 45 83% (35) 30 3.5 11 12.5
Barnes15 46 79% (63) 31 3.6 10.2 30.7
Marshall16 51 76% (22) 31 4.9 12.5 20.9
NB, no baseline measured; BMI, body mass index; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Scale; MSLT, Multiple Sleep Latency Test;











Points of improvement on the 
Epworth sleepiness scale
Figure 2 Forest plot indicating that Epworth sleepiness scores were
significantly improved by CPAP treatment. First author and year of
publication of source trial are listed on the vertical axis. Horizontal lines
represent 95% confidence intervals from each indicated study for the
effects of CPAP after adjustment for control. Elongated diamonds
indicate the mean (apex of diamond) and 95% confidence intervals for
the pooled estimate of the effect. The size of the shaded boxes represents
the weight given to that study. Larger boxes are studies that have given
more precise estimates and they tend to be larger.
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using funnel plots or either Begg’s or Egger’s tests for
publication bias with any of the three sleepiness measures.
However, these tests for bias need to be interpreted with
caution due to the combination of a few trials involving
relatively small numbers of patients.
ESS scores improved by 1.2 points compared with an
estimated background standard deviation of 4.5 points,19
giving an effect size of 0.27. MWT scores improved by
2.1 minutes compared with an estimated background stan-
dard deviation of 10.2 minutes,19 giving an effect size of 0.21.
These effects are small in magnitude.18
DISCUSSION
This meta-analysis has shown that CPAP significantly
reduces subjective daytime sleepiness, measured by the
ESS, by 1.2 points (95% CI 0.5 to 1.9, effect size 0.27) and
improves objective daytime wakefulness, measured by the
MWT, by 2.1 minutes (95% CI 0.5 to 3.7, effect size 0.21) in
patients with mild to moderate OSAS. There is insufficient
evidence to claim that CPAP decreases objective daytime
sleepiness, as measured by the MSLT, in these patients, as
sleep latencies worsened by a statistically non-significant
mean of 0.2 minutes (95% CI 21.0 to 0.6).
The estimated effect on MWT latencies should to be
interpreted with caution. Both trials15 16 that reported placebo
effects noted worsening on the placebo arm which is similar
or larger in magnitude to the benefit of CPAP estimated here
by meta-analysis. This unexpected pattern might indicate a
real effect where wakefulness is becoming subtly more
difficult to maintain in these patients about the time they
are invited to participate in a clinical trial. It could also be
evidence of a slight test-retest worsening of MWT latencies in
these crossover trials. The effect size estimated by the present
meta-analysis might not therefore be an accurate indication
of the smaller effect that would be seen in clinical practice
due to the lack of placebo adjustment. This might also be an
indication that CPAP halts a decline in wakefulness that
might be occurring in these patients.
The observed heterogeneity of the ESS was associated with
the dropout rate, trials with low dropout rates showing
significantly larger improvements. However, this might be a
chance finding as it is in the opposite direction to that
normally expected. Improvements in ESS scores were not
related to mean compliance with CPAP or baseline disease
severity (ESS or AHI), a series of potentially important
mediators. Neither the MSLT nor the MWT was observed to
have significant heterogeneity. Sensitivity analyses of all
three outcome measures did not indicate any studies which
had undue influence upon the final estimated effects of
CPAP. Funnel plots and associated statistics offered no
evidence that the effects observed were due to selective
publication, but this was to be expected given the relatively
small size of these trials. While the tests for publication bias
do not show statistical significance, it is always possible that
a number of unpublished negative trials exist.
The combination of parallel and crossover trials into a
single meta-analysis is not regarded as statistically orthodox
because the estimates of standard error are not calculated in
the same manner. However, when these study designs were
separated, both analyses agreed that CPAP has a small but
significant effect on subjective sleepiness that is also highly
comparable to the analysis shown in fig 2. Neither type of
study indicated any change in MSLT latencies, and this is also
highly comparable to the effects summarised in fig 4. Despite
this agreement, our combination of these studies into single
meta-analyses remains a potential study weakness.
These results extend the recent meta-analysis by Patel and
colleagues6 by meta-analysing not only improvements in the
ESS score, but also MSLT and MWT improvements in
patients with mild to moderate OSAS. Patel et al found that
the mean benefit to subjective sleepiness in patients with
mild to moderate OSAS was a non-significant 1.1 points in
the ESS score compared with a significant 4.75 points for
patients with largely severe OSAS. The finding here that
subjective sleepiness improved by 1.2 points is almost
identical in magnitude, but was statistically significant due
to the additional power from the three most recent studies.
The applicability of the findings here is also strengthened by
the exclusion from the analyses of the study by Barbe and
colleagues13 which used CPAP to treat people with severe
sleep disordered breathing but no abnormal daytime sleepi-
ness. The study was not relevant for deciding whether to treat
a group of patients with mild to moderate sleep disordered
breathing and significant daytime sleepiness. In the studies
analysed by Patel et al MWT latency improved by a mean of
3 minutes. Our finding of a 2.1 minute improvement in MWT
latencies in a group of studies restricted to patients with mild
to moderate OSAS is in accordance with expectations, given
that the findings of Patel et al included patients with the full
spectrum of OSAS severity (including mild to moderate). It is
notable that the trials at the severe end of the disease
spectrum analysed by Patel et al were of similar duration and
design to the trials of mild to moderate OSAS analysed here.
The greater effects seen in trials of severe OSAS are therefore
not due to longer treatment durations. The paucity of effect is
also not due to the poor action of the treatment as it has long
been established that CPAP abolishes sleep disordered
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Minutes of improvement in sleep latency
Figure 3 Forest plot indicating that Maintenance of Wakefulness Test
(MWT) sleep latencies were significantly improved by CPAP therapy.
First author and year of publication of source trial are listed on the
vertical axis. Horizontal lines represent 95% confidence intervals from
each indicated study for the effects of CPAP after adjustment for control.
Elongated diamonds indicate the mean (apex of diamond) and 95%
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Minutes of improvement in sleep latency
Figure 4 Forest plot indicating that Multiple Sleep Latency Test (MSLT)
sleep latencies were not significantly improved by CPAP therapy. First
author and year of publication of source trial are listed on the vertical
axis. Horizontal lines represent 95% confidence intervals from each
indicated study for the effects of CPAP after adjustment for control.
Elongated diamonds indicate the mean (apex of diamond) and 95%
confidence intervals for the pooled estimate of the effect.
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While Patel and colleagues6 did not find significant
differences between MSLT and MWT treatment sensitivities,
we have from the outset assumed that these metrics should
not be combined as they measure different domains. MSLT
and MWT latencies in other studies are not well correlated,
are differentially sensitive to CPAP treatment, and probably
measure different abilities.27–29 Separating the ability to fall
asleep from the ability to sustain wakefulness also seems to
be supported by findings from the literature indicating that
these two phenomena arise from separate but interacting
neurological processes.30 The 95% confidence intervals from
the meta-analyses show that, while the MSLT scores are not
significantly affected by CPAP treatment, the MWT scores are
significantly improved (figs 2 and 3). Furthermore, these
latencies are significantly different when combined in the
same meta-analysis. We therefore conclude that MSLT and
MWT latencies should not be combined, despite being
measured in compatible units, because the two measure-
ments are differentially sensitive to CPAP treatment and
probably measure different aspects of increased sleepiness, at
least in the specific patient group included here.
The improvements in sleepiness in this group are statisti-
cally significant, but it is not clear from the present analyses
whether the benefit accrues equally to those across the mild
to moderate spectrum or whether there exists a mean severity
point at which CPAP therapy is more of a hindrance to good
sleep than the sleep disordered breathing it treats. It is also
unclear whether the expense associated with ongoing CPAP
treatment is cost effective in terms of the effects on daytime
sleepiness. Cost effectiveness is an important consideration
because the effect sizes are very small and close to being
insignificant (,0.20).18 CPAP might have an expanded role in
treating mild to moderate OSAS if it can be shown in
randomised controlled trials to be a cost effective treatment
for reducing the risk of cardiovascular disease.
In conclusion, CPAP significantly improves subjective
sleepiness and objective wakefulness in patients with mild
to moderate OSA; it does not improve objective sleepiness.
However, the effect sizes of these adjustments are very small
and may not be clinically relevant.
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